1. Home
  2. GERN

as of 03-03-2026 3:38pm EST

$1.46
$0.09
-6.13%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Founded: 1990 Country:
United States
United States
Employees: 229 City: FOSTER CITY
Market Cap: 1.1B IPO Year: N/A
Target Price: $2.17 AVG Volume (30 days): 16.5M
Analyst Decision: Hold Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $1.04 - $2.01 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 32.27% Revenue Growth (next year): 60.16%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered GERN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 73.28%
73.28%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: